LifeStance Health Group (LFST) Fundamentals 2026 — P/E 183.8x, Revenue Analysis | SniperIQ
LifeStance Health Group (LFST) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of $4.3B, trading at
1.06 on the NASDAQ. This SniperIQ fundamentals page covers LifeStance Health Group's valuation (P/E 183.8x, P/B 2.9x), profitability (net margin 1.6%), revenue (
.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$4.3B
P/E (TTM)183.8x
Net Margin1.6%
Revenue (FY25)
.4B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is LifeStance Health Group's market cap?
LifeStance Health Group (LFST) has a market capitalization of approximately $4.3B, trading at
1.06 on the NASDAQ. Market cap moves with the live share price.
What is LifeStance Health Group's P/E ratio?
LifeStance Health Group's trailing twelve-month P/E ratio is 183.8x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LifeStance Health Group?
LifeStance Health Group runs a net profit margin of 1.6%, a gross margin of 32.6%, and an operating margin of 3.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LifeStance Health Group generate?
LifeStance Health Group reported revenue of
.4B for fiscal year 2025, with net income of
0M and earnings per share (EPS) of 0.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LifeStance Health Group pay a dividend?
LifeStance Health Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is LifeStance Health Group financially healthy?
LifeStance Health Group carries a debt-to-equity ratio of 0.13x and a current ratio of 1.48x, with a market beta of 1.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LifeStance Health Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LifeStance Health Group (LFST) the key facts are: market cap $4.3B, P/E 183.8x, revenue
.4B, 52-week range 3.74-11.76. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LifeStance Health Group's full fundamentals live
Get LifeStance Health Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.